Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients
…, Y Abe, A Tamakoshi, M Doyu, M Hirayama, G Sobue - Brain, 2002 - academic.oup.com
We investigated the disease progression and survival in 230 Japanese patients with multiple
system atrophy (MSA; 131 men, 99 women; 208 probable MSA, 22 definite; mean age at …
system atrophy (MSA; 131 men, 99 women; 208 probable MSA, 22 definite; mean age at …
[PDF][PDF] Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy
…, H Niwa, C Sang, Y Kobayashi, M Doyu, G Sobue - Neuron, 2002 - cell.com
Spinal and bulbar muscular atrophy (SBMA) is a polyglutamine disease caused by the
expansion of a CAG repeat in the androgen receptor (AR) gene. We generated a transgenic …
expansion of a CAG repeat in the androgen receptor (AR) gene. We generated a transgenic …
Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease
Neuronal intranuclear inclusion disease (NIID) is a progressive neurodegenerative disease
that is characterized by eosinophilic hyaline intranuclear inclusions in neuronal and somatic …
that is characterized by eosinophilic hyaline intranuclear inclusions in neuronal and somatic …
A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome)
…, M Mikuni, H Kumashiro, K Higashi, G Sobue… - Nature …, 1998 - nature.com
Wolfram syndrome (WFS; OMIM 222300) is an autosomal recessive neurodegenerative
disorder defined by young-onset non-immune insulin-dependent diabetes mellitus and …
disorder defined by young-onset non-immune insulin-dependent diabetes mellitus and …
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive
research, current management of amyotrophic lateral sclerosis remains suboptimal from …
research, current management of amyotrophic lateral sclerosis remains suboptimal from …
Demyelinating and axonal features of Charcot–Marie–Tooth disease with mutations of myelin‐related proteins (PMP22, MPZ and Cx32): a clinicopathological study of …
…, T Saito, K Nakashima, J Kira, R Kaji, N Oka, G Sobue - Brain, 2003 - academic.oup.com
Three genes commonly causing Charcot–Marie–Tooth disease (CMT) encode myelin‐related
proteins: peripheral myelin protein 22 (PMP22), myelin protein zero (MPZ) and connexin …
proteins: peripheral myelin protein 22 (PMP22), myelin protein zero (MPZ) and connexin …
[HTML][HTML] Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
…, A Genge, PJ Shaw, G Sobue… - … England Journal of …, 2022 - Mass Medical Soc
Background The intrathecally administered antisense oligonucleotide tofersen reduces
synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with …
synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with …
X-linked recessive bulbospinal neuronopathy: a clinicopathological study
GEN Sobue, Y HASHIZUME, E MUKAI, M HIRAYAMA… - Brain, 1989 - academic.oup.com
A clinicopathological study on X-linked recessive bulbospinal neuronopathy was undertaken
on 9 cases, with morphological observations on 3 autopsied cases and sural nerve …
on 9 cases, with morphological observations on 3 autopsied cases and sural nerve …
A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ
…, K Kouyama, M Doyu, G Sobue… - Proceedings of the …, 2001 - National Acad Sciences
Through functional expression screening, we identified a gene, designated Humanin (HN)
cDNA, which encodes a short polypeptide and abolishes death of neuronal cells caused by …
cDNA, which encodes a short polypeptide and abolishes death of neuronal cells caused by …
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
K Abe, M Aoki, S Tsuji, Y Itoyama, G Sobue… - The Lancet …, 2017 - thelancet.com
Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …